These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 30007561)

  • 1. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
    Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
    Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
    Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
    Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study.
    Morais RDVS; Sogorb-González M; Bar C; Timmer NC; Van der Bent ML; Wartel M; Vallès A
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.
    Spronck EA; Brouwers CC; Vallès A; de Haan M; Petry H; van Deventer SJ; Konstantinova P; Evers MM
    Mol Ther Methods Clin Dev; 2019 Jun; 13():334-343. PubMed ID: 30984798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy.
    Vallès A; Evers MM; Stam A; Sogorb-Gonzalez M; Brouwers C; Vendrell-Tornero C; Acar-Broekmans S; Paerels L; Klima J; Bohuslavova B; Pintauro R; Fodale V; Bresciani A; Liscak R; Urgosik D; Starek Z; Crha M; Blits B; Petry H; Ellederova Z; Motlik J; van Deventer S; Konstantinova P
    Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models.
    Sogorb-Gonzalez M; Landles C; Caron NS; Stam A; Osborne G; Hayden MR; Howland D; van Deventer S; Bates GP; Vallès A; Evers M
    Brain; 2024 Dec; 147(12):4043-4055. PubMed ID: 39155061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology.
    Spronck EA; Vallès A; Lampen MH; Montenegro-Miranda PS; Keskin S; Heijink L; Evers MM; Petry H; Deventer SJV; Konstantinova P; Haan M
    Brain Sci; 2021 Jan; 11(2):. PubMed ID: 33498212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes.
    Keskin S; Brouwers CC; Sogorb-Gonzalez M; Martier R; Depla JA; Vallès A; van Deventer SJ; Konstantinova P; Evers MM
    Mol Ther Methods Clin Dev; 2019 Dec; 15():275-284. PubMed ID: 31737741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A transgenic minipig model of Huntington's Disease.
    Baxa M; Hruska-Plochan M; Juhas S; Vodicka P; Pavlok A; Juhasova J; Miyanohara A; Nejime T; Klima J; Macakova M; Marsala S; Weiss A; Kubickova S; Musilova P; Vrtel R; Sontag EM; Thompson LM; Schier J; Hansikova H; Howland DS; Cattaneo E; DiFiglia M; Marsala M; Motlik J
    J Huntingtons Dis; 2013; 2(1):47-68. PubMed ID: 25063429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy
    Wang W; Zhou P; Wang X; Chen F; Christensen E; Thompson J; Ren X; Kells A; Stanek L; Carter T; Hou J; Sah DWY
    Hum Gene Ther; 2022 Jan; 33(1-2):37-60. PubMed ID: 34806402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minipigs as a Large-Brained Animal Model for Huntington's Disease: From Behavior and Imaging to Gene Therapy.
    Reilmann R; Schuldenzucker V
    Methods Mol Biol; 2018; 1780():241-266. PubMed ID: 29856023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gradual Phenotype Development in Huntington Disease Transgenic Minipig Model at 24 Months of Age.
    Vidinská D; Vochozková P; Šmatlíková P; Ardan T; Klíma J; Juhás Š; Juhásová J; Bohuslavová B; Baxa M; Valeková I; Motlík J; Ellederová Z
    Neurodegener Dis; 2018; 18(2-3):107-119. PubMed ID: 29870995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene silencing approaches for the treatment of Huntington's disease].
    Merienne N; Déglon N
    Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.